Fabrice André, MD, PhD, received his M.D. in Grenoble in 2002, and a PhD in Biotechnology from Paris University in 2005.
He spent one year as visiting assistant professor at the University of Texas, MD Anderson Cancer Center and was a past recipient of Young Investigator and Career Development awards from the American Society of Clinical Oncology (ASCO).
He is currently Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Professor André is conducting research in the field of biomarkers and personalised therapies. His research work focuses on biomarker discovery, development of targeted agents and implementation of personalised medicine. His team includes 50 people working on basic sciences, bioinformatics, biotechnologies and clinical research. Professor André is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system.
He has published more than 100 peer reviewed papers, including papers in the New England Journal of Medicine, Lancet, Nature Medicine, Journal of Clinical Oncology and Lancet Oncology, either as main or co-author.
Professor André is chairman of the biomarker group at UNICANCER (French cooperative group). He was member of several scientific committees for international meetings, including ECCO, ESMO, and IMPAKT.